Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06008925 Org: User:
Start: 11/17/22 End: 06/30/26 Due: 06/30/27

Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06746480 Org: User:
Start: 03/19/22 End: 12/01/25 Due: 12/01/26

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT06113731 Org: User:
Start: 07/10/23 End: 10/31/24 Due: 10/31/25

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT06126510 Org: User:
Start: 07/18/23 End: 01/17/26 Due: 01/17/27

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04806464 Org: User:
Start: 03/16/21 End: 12/31/24 Due: 12/31/25

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04758897 Org: User:
Start: 04/14/21 End: 12/01/22 Due: 12/01/23

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06124001 Org: User:
Start: 11/30/23 End: 06/30/26 Due: 06/30/27

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT06113744 Org: User:
Start: 03/10/23 End: 06/30/24 Due: 06/30/25